

Made possible by

MELOMA &  
MELANOMA  
SOCIETY  
is now  
**Blood Cancer  
United**  
PLATINUM SPONSOR

**Genentech**  
A Member of the Roche Group  
SILVER SPONSOR

**GRAIL**  
BRONZE SPONSOR

**UCSF** Helen Diller Family  
Comprehensive  
Cancer Center  
FRIENDS OF FORUM SPONSOR

Music by Marc Anthony, *Vivir mi Vida*,  
From the Album, *3.0*

The Latino Cancer Institute

# 7<sup>th</sup> Annual National Friday Forum Series

Sept 12th, Oct 3rd, Oct 24th



THE LATINO CANCER INSTITUTE

Connect. Convene. Advocate.

# You Are In The Waiting Room

## Hour One

**Keynote:** Luis Arturo Valdez, PhD, MPH  
Drexel University, PA

Lisa Goldman Rosas, PhD, MPH  
Stanford School of Medicine, CA

## Hour Two

Luis Carvajal-Carmona, PhD, University of California, Davis

María Constanza Camargo, PhD, MS, MHA  
National Cancer Institute (NIH/NCI), MD

Enrique Velazquez-Villarreal, MD, PhD, MPH, MS  
City of Hope, Duarte Cancer Center, CA

## Hour Three

Leticia Nogueira, PhD, MPH, American Cancer Society (ACS)

Catherine Metayer, MD, PhD  
University of California, Berkeley

Katherine A. McGlynn, PhD, MPH  
National Institutes of Health (NIH/NCI), MD



October is Breast & Liver Cancer Awareness Month



THE LATINO CANCER INSTITUTE  
Connect. Convene. Advocate.



# Addressing an Unanswered Burden - Latino Men's Health & Cancer

October 3rd, 2025

Made possible by



HEALTH IS WEALTH

Raise  
Awareness

Discover  
Risks

## Aims

Gain Awareness of Latino Men's  
Cancer Burden

Increase  
Research

Increase  
Latino-Focused  
Clinical Trials

Promote  
Latino Male  
Researchers

“Breast cancer” Google searches were found to be 36.7% (95% CI, 34% - 39%) more frequent than “prostate cancer” per month from 2009-2019.

[https://www.researchgate.net/publication/349291406\\_Using\\_Google\\_Trends\\_and\\_Twitter\\_for\\_Prostate\\_Cancer\\_Awareness\\_A\\_Comparative\\_Analysis\\_of\\_Prostate\\_Cancer\\_Awareness\\_Month\\_and\\_Breast\\_Cancer\\_Awareness\\_Month](https://www.researchgate.net/publication/349291406_Using_Google_Trends_and_Twitter_for_Prostate_Cancer_Awareness_A_Comparative_Analysis_of_Prostate_Cancer_Awareness_Month_and_Breast_Cancer_Awareness_Month)

# Latino Men and Breast Cancer

## Spain - BRCA2 germ-line mutations in Spanish male breast cancer patients (pub Jan 2000)

- Screened DNA from 11 affected men and 6 women with breast cancer (BC) who had an affected male relative (father or brother)
- There is an association between BRCA2 mutations and male breast cancer, especially in those with a family history of BC.
- High prevalence of BRCA2 mutations among males should be considered when estimating risk for female relatives.

Authors recommend all new male cases of BC should be regarded as being possibly inherited and should be fully investigated.

BRCA2 germ-line mutations in Spanish male breast cancer patients  
Q Díez I, J Cortés, M Domènech, C Pericay, J Brunet, C Alonso, M Baiget Affiliations \* PMID: 10690392  
\*DOI: [10.1023/a:1008339009528](https://pubmed.ncbi.nlm.nih.gov/10690392/) 2000 Jan. <https://pubmed.ncbi.nlm.nih.gov/10690392/>

## Mexico - Multi-Center Series 2025, clinical characteristics of male patients with breast cancer.." (pub Feb 2025)

49 Latino men - mean dx age ~65

- ~22% stage IV at diagnosis
- ~12% triple-negative, high-grade tumors common
- ~8% pathogenic BRCA among those tested
- Notable endocrine resistance rates –

Authors call for deeper molecular profiling

Clinical characteristics of male patients with breast cancer in the Latino population  
Carlos González-Núñez †, Alejandro Mohar †, Nancy Revnoso-Noverón †, Rosa María Álvarez-Gómez †, Yanin Chavarri-Guerra †, Sergio Aguilar-Villanueva †, Raúl Guzmán-Tricoueros †, Areli Velázquez-Martínez †, Talía Weisman-Ostrosky †, Fanny Potras-Reyes †, Alexandra Garcilazo †, Claudia Arce †, Juan Enrique Barcoallo-Rocha †, Paula Cabrera-Galeana † Affiliations \* PMID: 39470849 \*DOI: [10.1007/s10549-024-07525-1](https://pubmed.ncbi.nlm.nih.gov/39470849/) <https://pubmed.ncbi.nlm.nih.gov/39470849/> Feb

# All Cancer Sites – Incidence and Mortality for Hispanic/Latino Males and Females

## Incidence (2018-2022)

- Hispanic Males: ~ 372.3 per 100,000
- Hispanic Females: ~ 357.6 per 100,000

## Mortality (2019-2023)

- Hispanic Males: ~ 124.4 per 100,000
- Hispanic Females: ~ 93.2 per 100,000

SEER DATA

# Current U.S. Rates for Hispanic/Latino Men and Women

Source: American Cancer Society Facts and Figures for Hispanic Latino People 2024-2026

## Incidence (2017-2021)

- Lung & bronchus: Men 33.6 | Women 24.6
- Skin (melanoma): Men 5.1 | Women 5.0
- Leukemia (acute lymphocytic\*): Men 6.0 | Women 4.7
- Colorectal (colon & rectum): Men 38.2 | Women 27.5
- Liver & intrahepatic bile duct: Men 20.3 | Women 8.7
- Stomach: Men 11.4 | Women 9.8
- Gallbladder: Men 1.3 | Women 2.4

## Mortality (2018-2022)

- Lung & bronchus: Men 19.4 | Women 11.1
- Skin (melanoma): Men 0.8 | Women 0.5
- Leukemia (acute lymphocytic\*): Men 0.7 | Women 0.6
- Colorectal: Men 13.4 | Women 8.5
- Liver & intrahepatic bile duct: Men 12.6 | Women 6.1
- Stomach: Men 5.7 | Women 3.8
- Gallbladder: Men 0.5 | Women 1.0

# Thanks to the Sponsors Who Make these Forums Possible



is now

**Blood Cancer  
United**

PLATINUM SPONSOR

**Genentech**

*A Member of the Roche Group*

SILVER SPONSOR

**GRAIL**

BRONZE SPONSOR

**UCSF** Helen Diller Family  
Comprehensive  
Cancer Center

FRIENDS OF THE FORUM SPONSOR

## Hour One

**Keynote:** Luis Arturo Valdez, PhD, MPH  
Drexel University, PA

Lisa Goldman Rosas, PhD, MPH  
Stanford School of Medicine, CA

## Hour Two

Luis Carvajal-Carmona, PhD, University of California, Davis

María Constanza Camargo, PhD, MS, MHA  
National Cancer Institute (NIH/NCI), MD

Enrique Velazquez-Villarreal, MD, PhD, MPH, MS  
City of Hope, Duarte Cancer Center, CA

## Hour Three

Leticia Nogueira, PhD, MPH, American Cancer Society (ACS)

Catherine Metayer, MD, PhD  
University of California, Berkeley

Katherine A. McGlynn, PhD, MPH  
National Institutes of Health (NIH/NCI), MD

## Coming Up

**October 24<sup>th</sup>**



Building the Latino Medical Student/Physician Pipeline! Cristhian Gutierrez Huerta, Latino Medical Student Association (Chicago)  
& Dr. Elena Rios, National Hispanic Health Foundation (Washington, D.C.)

HEALTH IS WEALTH

# Housekeeping

- Keep your cameras off, and mic on mute
- Use the Chat Box for questions for our speakers
- Various documents also found in the Chat Box
- All the presentations are being recorded. Slides and recordings will be available after Nov.1st

## PARA ESPAÑOL

- En los controles de su reunión/seminario web en la parte inferior de su pantalla, haga clic en  "Interpretación" y elija español.
- Si no ve el ícono de Interpretación en los controles de su reunión/seminario web, haga clic en el ícono "Más"  y seleccione Interpretación de la lista.
- Para escuchar solo español, haga clic en "Silenciar audio original."



## Interpreters



Fabiola Rivera Ramirez




Maria Esperanza Outeirino-Feijoo




Claudia Schalesky

# About Machismo - Moderate to Strong Influence

Which TLCI Forum topics interest you most? (Select up to 3)



How much do you think machismo influences Latino men's health-seeking behavior?



\* Small sample size – 16 respondents



**Keynote:**

# **Breaking Down Machismo: What Happens When Old Scripts Meet New Realities**

**Luis Arturo Valdez, PhD, MPH**

Assistant Professor, Community Health and Prevention,  
Founder of the Ganas Health Initiative, Drexel University,  
Dornsife School of Public Health, PA

***Breaking Down Machismo:  
What Happens When Old Scripts  
Meet New Realities***

Luis Arturo Valdez, PhD, MPH  
Assistant Professor, Dornsife School of Public Health, Drexel University  
***GANASHEALTH.org***

# THE 'MARLBORO MAN'



What does it mean to “be a man”?

# THE “MAN BOX”

**DON'T CRY**


**BE TOUGH**

**DON'T BE 'LIKE A  
WOMAN'**

**BE STRONG**


**BE INDEPENDENT**

# “MACHISMO” A LEGACY OF COLONIZATION, CATHOLICISM, AND PATRIARCHY



**THE HEALTH COSTS:  
*WHEN MACHISMO BECOMES A PRESSURE COOKER***

# PATRIARCHY AND CANCER: *SILENCE BECOMES DEADLY*



**Avoidance of preventive care:** fewer screenings for prostate, colorectal, and lung cancer.

**Later-stage diagnosis:** higher mortality in Latino men.

**Cultural + structural barriers:** machismo + low access = deadly delays.

**Smoking & masculinity:** marketed as toughness → increased lung cancer risk.



# SO WHAT?

- 1. More than a stereotype**
- 2. How do we “bring men in”?**
- 3. Setting the stage for behavior change**

# MORE THAN A STEREOTYPE



# THE WATER WE (ALL) SWIM IN



# ENTERING A REFLEXIVE PROCESS: *RETHINKING HOW WE SEE MEN*



**“BRINGING MEN IN”**  
***MEETING MEN WHERE THEY ARE***

**INTERROGATING THE BAR:**  
***THE STANDARDS WE SET, SHAPE THE MEN WE SEE***

# THE GANAS HEALTH INITIATIVE

## *GENDER-TRANSFORMATIVE HEALTH*

**GANAS: Group-based,  
culturally grounded**

**Tackles stress, masculinity,  
health behaviors**

**Builds community + supports  
multiple behavior change**



# **CALLS TO ACTION**

## ***FROM REFLECTION TO ACTION***

**Reflect:** Question our assumptions about men

**Disrupt:** Challenge stereotypes and silence

**Build:** Create spaces for men's growth and care

**Partner:** Support TRANSFORMATIVE work

# Obesity in America, An Escalating Crisis

## THE TREND:

In just 6 years, states with severe obesity ( $\geq 35\%$ ) more than tripled –

- 2018: 7 states
- 2024: 23 states (Midwest & South hit hardest)

## THE DISPARITY:

Communities of color face the greatest burden –

- Black adults: 38 states at  $\geq 35\%$
- Hispanic adults: 34 states at  $\geq 35\%$

## THE REALITY:

All U.S. states and territories now have adult obesity rates above 20%, with only Colorado and D.C. still below 25%



# Addressing the Triple Threat: Meeting Latino Men Where They Are

**Lisa Goldman Rosas, PhD, MPH**

Associate Professor, Department of Epidemiology and Population Health, Stanford School of Medicine Food for Health Equity Lab, Co-Director of Community-Engaged Research, Office of Cancer Equity, Stanford Cancer Institute, CA

# Addressing the Triple Threat: Meeting Latino Men Where They Are

Lisa Goldman Rosas, PhD MPH

Associate Professor, Department of  
Epidemiology and Population Health &  
Department of Medicine (Primary Care and  
Population Health)

Latino Cancer Institute 2025 Men's Health  
Forum



# Triple Threat: Obesity, Diabetes, and Cancer

**Obesity:** Latino men have the highest prevalence compared to men of all other racial/ethnic groups

**Diabetes:** Latino men have a higher prevalence compared to white men

**Cancer:** Obesity increases risk for 13 cancers; liver cancer disproportionately impacts Latino men



## Cancer Facts & Figures for Hispanic/Latino People 2024-2026

Incidence, 2017-2021		Male	
	Hispanic	White	Rate Ratio
Acute lymphocytic leukemia	6.0	3.7	1.59
Breast (female)			
Colon & rectum <sup>a</sup>	38.2	40.1	0.95
Gallbladder	1.3	0.7	1.94
Kidney & renal pelvis	23.6	24.3	0.97
Liver & intrahepatic bile duct	20.3	11.2	1.81
Lung & bronchus	33.6	63.9	0.53
Melanoma	5.1	38.1	0.13
Non-Hodgkin lymphoma	20.5	24.2	0.85
Oral cavity & pharynx	10.8	20.7	0.52
Ovary			
Pancreas	13.1	15.8	0.83
Prostate	92.9	114.5	0.81
Stomach	11.4	7.1	1.60
Uterine cervix			
Uterine corpus			
<b>All sites</b>	<b>378.5</b>	<b>513.0</b>	<b>0.74</b>
Mortality, 2018-2022		Male	
	Hispanic	White	Rate Ratio
Acute lymphocytic leukemia	0.7	0.4	1.68
Breast (female)			
Colon & rectum	13.4	15.2	0.88
Gallbladder	0.5	0.3	1.56
Kidney & renal pelvis	4.7	5.3	0.88
Liver & intrahepatic bile duct	12.6	8.4	1.50
Lung & bronchus	19.4	41.2	0.47
Melanoma	0.8	3.8	0.22
Non-Hodgkin lymphoma	5.4	6.9	0.79
Oral cavity & pharynx	2.4	4.3	0.56
Ovary			
Pancreas	9.7	13.2	0.73
Prostate	15.4	18.1	0.85
Stomach	5.7	2.8	2.04
Uterine cervix			
Uterine corpus			
<b>All sites</b>	<b>126.8</b>	<b>179.0</b>	<b>0.71</b>

# Addressing the Triple Threat

- Research to identify effective intensive lifestyle interventions has been based primarily on research with non-Latinx white women
- A systematic review documented only 546 Latino men (4%) among 15,356 participants in behavioral weight loss intervention trials






# The HOMBRE Trial

---


Hombres con **Opciones** para **Mejorar**  
su **Bienestar** y **Reducir Enfermedades**  
crónicas



# The HOMBRE Trial



- 18 month follow-up
- Primary outcome: Proportion of men who achieve 5% weight loss



Qualitative interviews according to RE-AIM with participants, health coaches, and staff

# HOMBRE



Facilitated  
choice of  
modality

In-person  
groups

Virtual  
groups

Self-  
directed

Group sessions



Group sessions on zoom



Online videos



# HOMBRE

**Table 1.** Session delivery options in the HOMBRE (Hombres con Opciones para Mejorar su Bienestar y Reducir Enfermedades Crónicas) intervention.

Characteristics	Videoconference	Web-based videos	In person
Description	<ul style="list-style-type: none"><li>• A bilingual, bicultural coach facilitated weekly sessions on a videoconferencing platform (Zoom)</li></ul>	<ul style="list-style-type: none"><li>• Men were given access to pre-recorded web-based videos of coach-facilitated group sessions</li></ul>	<ul style="list-style-type: none"><li>• A bilingual, bicultural coach facilitated weekly sessions at the clinic where men were recruited</li></ul>

# HOMBRE: Participants

**Table 1. Baseline participant characteristics overall and by treatment group<sup>a</sup>**

Characteristic	HOMBRE (n=212)	Minimal Intensity (n=212)
Age, year <sup>b</sup>	47.0 ± 11.8	47.1 ± 12.1
Age category, %		
18-<45	45.8	44.8
45-<65	46.7	49.1
65+	7.5	6.1
Education, %, n=207, 202		
High school/GED or less	22.7	17.8
Some college	25.6	28.2
College graduate	29.5	32.2
Post college	22.2	21.8
Preferred language, %, n=207, 203		
English	85.5	85.7
Spanish	14.5	14.3

# HOMBRE: Outcomes

**Table 2. Primary and secondary outcomes**

Outcome measures	Unadjusted mean change $\pm$ SD		Adjusted mean treatment difference (95% CI) <sup>a</sup>	P value <sup>a</sup>
	HOMBRE Intervention	Minimal Intensity		
<b>Primary outcome<sup>b</sup></b>				
At least 5% weight loss from baseline, no. (%), n =186, 180				
18 months	51 (27.4)	37 (20.6)	7.2 (-1.8, 17.0)	0.13
<b>Posthoc exploratory outcome</b>				
Weight change from baseline, kg				
6 months	-2.78 $\pm$ 5.45	-1.79 $\pm$ 6.10	-1.20 (-2.23, -0.17)	<b>0.02</b>
12 months	-2.77 $\pm$ 6.47	-1.56 $\pm$ 7.00	-1.10 (-2.10, -0.11)	<b>0.03</b>
18 months	-2.46 $\pm$ 6.60	-1.67 $\pm$ 6.16	-1.01 (-2.06, 0.05)	0.06

# Intervention choice

**Table 2.** Baseline characteristics overall and by initial choice of intervention delivery (N=200).

Characteristic	All	Videconference (n=56)	Web-based videos (n=62)	In-person group (n=82)	P value
<b>Demographic</b>					
Age (years), mean (SD)	47.3 (11.8)	45.6 (10.9) <sup>a</sup>	45.4 (11.4) <sup>a</sup>	50.0 (12.3) <sup>b</sup>	.03
<b>Income (US \$; n=167), n (%)</b>					
<75,000	49 (29.3)	8 (16) <sup>a</sup>	14 (25.9) <sup>a,b</sup>	27 (42.9) <sup>b</sup>	.02
75,000-<150,000	53 (31.7)	17 (34) <sup>a</sup>	17 (31.5) <sup>a,b</sup>	19 (30.2) <sup>b</sup>	
≥150,000	65 (38.9)	25 (50) <sup>a</sup>	23 (42.6) <sup>a,b</sup>	17 (27) <sup>b</sup>	
<b>Education (n=195), n (%)</b>					
High school, GED <sup>c</sup> , or less	45 (23.1)	7 (12.7) <sup>a</sup>	12 (19.7) <sup>a,b</sup>	26 (32.9) <sup>b</sup>	.03
Some college	49 (25.1)	12 (21.8) <sup>a</sup>	19 (31.1) <sup>a,b</sup>	18 (22.8) <sup>b</sup>	
College graduate	58 (29.7)	17 (30.9) <sup>a</sup>	21 (34.4) <sup>a,b</sup>	20 (25.3) <sup>b</sup>	
More than college	43 (22.1)	19 (34.5) <sup>a</sup>	9 (14.8) <sup>a,b</sup>	15 (19) <sup>b</sup>	
<b>Language<sup>d</sup>, n (%)</b>					
English	142 (71)	48 (85.7) <sup>a</sup>	61 (98.4) <sup>b</sup>	33 (40.2) <sup>b</sup>	<.001
Spanish	58 (29)	8 (14.3) <sup>a</sup>	1 (1.6) <sup>b</sup>	49 (59.8) <sup>b</sup>	
<b>Acculturation score, mean (SD)</b>					
	3.4 (0.9)	3.7 (0.6) <sup>a</sup>	3.6 (0.7) <sup>a</sup>	3.1 (1.0) <sup>b</sup>	<.001

# HOMBRE outcomes

**Table 5.** Weight change by initial and final choice of intervention delivery (N=200).

Weight change <sup>a</sup>	Initial intervention choice, mean (SD)			Final intervention choice, mean (SD)		
	Videoconference (n=56)	Web-based videos (n=62)	In-person group (n=82)	Videoconference (n=45)	Web-based videos (n=77)	In-person group (n=78)
Weight change at 6 months from baseline (kg)	-3.9 (6.1) <sup>b</sup>	-0.3 (3.7)	-4.3 (5.3) <sup>b</sup>	-4.8 (5.7) <sup>b</sup>	-0.4 (4.3)	-4.4 (5.3) <sup>b</sup>
Weight change at 12 months from baseline (kg)	-3.4 (7.0)	-1.0 (4.8)	-4.1 (6.0) <sup>c</sup>	-4.5 (8.0) <sup>c</sup>	-0.6 (4.8)	-4.2 (6.1) <sup>c</sup>
Weight change at 18 months from baseline (kg)	-3.8 (8.4) <sup>d</sup>	-0.9 (4.6)	-3.3 (6.0) <sup>d</sup>	-4.8 (8.6) <sup>c</sup>	-0.8 (4.6)	-3.2 (6.2) <sup>d</sup>

The flexibility  
of the  
intervention  
was  
frequently  
mentioned in  
interviews



“...I think given my schedule, having the flexibility to either do it yourself at your own pace, meaning on demand, versus having to stick to a schedule, it's pretty helpful, actually..”



“...think it's very appealing, because depending on your lifestyle or how busy you are, you are provided three options, which I think is very flexible..”

# Lessons Learned

Latino men can be engaged in lifestyle interventions to address the triple threat!


Offering choice was a key feature for men

Two-thirds of men chose a technology-mediated option

Men who chose one of the coach-facilitated methods lost more weight than those who chose the online videos

# What You Told Us: Survey Insights

## Opinions on Biggest Contributors to Cancer Risk



## Complexity Mindset

68%: All factors equally contribute to cancer risk

## No Consensus on Genetics/ Opinion Split

31%: A little influence  
31%: Moderate influence  
25%: Strong influence  
12%: Not sure

## AI: Informed but Cautious

81%: Use Chat GPT  
37%: Bias Concerns  
25%: Inequality  
68%: Want - Equity

# Hispanic / Latinos are nation's second-largest racial or ethnic group after non-Hispanic whites

\*From CENSUS 2023

Hispanics make up 19.2% of the U.S. population or 65.2 Million people\*

## Largest Subpopulations\*

Mexican	58.9%
Central American	10.3%
Puerto Rican	9.3%
South American	7.3%
Cuban	3.8%
Dominicans	3.8%

\*\* From CDC

In 2023, an estimated 194,500 U.S. Hispanics were diagnosed with cancer

1 in 5 Latino deaths due to cancer. Source ACS

In 2023 An estimated 50,000 Hispanics died from the disease

16.8% of Hispanics/Latinos (of any race) had **no health insurance** coverage compared to 5.3% of non-Hispanic whites.  
 51.5% of Hispanics/Latinos (of any race) had **private health insurance coverage**, compared to 74.1% of non-Hispanic whites.  
 37.9% of Hispanics/Latinos had **public health insurance**, compared to 36.1% of non-Hispanic whites.



# Colorectal Cancer in Latino Populations: A Focus on Men and Emerging Challenges

**Luis Carvajal-Carmona, PhD**

Associate Vice Chancellor, Office of Academic Diversity Cancer Genetics Researcher, Professor, Dept of Biochemistry and Molecular Medicine, Co-Director of Community Engagement Program, Clinical and Translational Science Center; Principal Investigator, Carvajal-Carmona Lab University of California, Davis

# Colorectal Cancer in Latinos: Emerging Challenges


**Luis G Carvajal-Carmona, PhD**

Associate Vice Chancellor and  
Professor of Biochemistry and Molecular Medicine

University of California, Davis

# Colorectal cancer in Latinos

Figure 2. Leading Sites of New Cancer Cases and Deaths among Hispanic People – 2021 Estimates



\*Estimates exclude basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates do not reflect the impact of the COVID-19 pandemic on cancer cases or deaths (see Sources of Statistics, page 31, for more information).


# Latino CRC Epidemiology

Measure	Male	Female	Total
Incidence(per 100K)	32.3	27.5	30.0
Mortality (per 100K)	10.7	8.5	9.7
Number of Cases	9,800 (8.2%)	8,700 (7.2%)	18,500 (15.4%)
Number of Deaths	3,250 (7.2%)	2,550 (5.7%)	5,800 (12.9%)

Source: American Cancer Society, Cancer Facts & Figures for Hispanic/Latino People 2024–2026


### Colorectal Cancer Incidence Rates by Sex and Race/Ethnicity

Colorectal Cancer Incidence Rates by Sex and Race/Ethnicity in the US



### Colorectal Cancer Mortality Rates by Sex and Race/Ethnicity

Colorectal Cancer Mortality Rates by Sex and Race/Ethnicity in the US



# CRC Disparities in Latinos

- Over 56% of Latino patients are diagnosed at Stage III or IV, which is higher than White and Asian populations.
- Lower screening rates (49% vs. 58%)

# Why Do U.S. Cancer Health Disparities Exist?

Complex and interrelated factors contribute to cancer health disparities in the United States. Adverse differences in many, if not all, of these factors are directly influenced by structural and systemic racism. The factors may include, but are not limited to, differences or inequalities in:

## ENVIRONMENTAL FACTORS

- Air and water quality
- Transportation
- Housing
- Community safety
- Access to healthy food sources and spaces for physical activity



## BEHAVIORAL FACTORS

- Tobacco use
- Diet
- Excess body weight
- Physical inactivity
- Adherence to cancer screening and vaccination recommendations



## SOCIAL FACTORS

- Education
- Income
- Employment
- Health literacy



## CLINICAL FACTORS

- Access to health care
- Quality of health care



## CULTURAL FACTORS

- Cultural beliefs
- Cultural health beliefs




## PSYCHOLOGICAL FACTORS

- Stress
- Mental health



## BIOLOGICAL AND GENETIC FACTORS



# Drivers of Disparities

- Structural and Systemic Barriers
- Lower Screening Rates
- Genetic/Molecular Differences
- Cultural and Psychosocial Factors
- Environmental and Social Determinants

Uncovering multilevel drivers of cancer disparities among Latinos in the United States


Amelie G. Ramirez<sup>1\*</sup>, Edgar Munoz<sup>1</sup>,  
Lorna Rodriguez-Rodriguez<sup>2</sup>, Leon Bernal-Mizrachi<sup>4</sup>,  
Jose Aron Lopez<sup>4</sup>, Paulo S. Pinheiro<sup>5</sup>,  
Barbara Segarra-Vasquez<sup>3</sup>, Gregory Talavera<sup>6</sup>,  
Luis G. Carvajal-Carmona<sup>6</sup>, Adolfo Diaz Duque<sup>1</sup>, Cliff Despres<sup>1</sup>  
and Edward J. Tapido<sup>3</sup>

# CRC in Latin America: The role of Westernization

- **Diet:** Increased intake of red and processed meats, sugar, and refined grains
- **Lifestyle:** Sedentary habits, urban living, and decreased physical activity
- **Healthcare Access:** Delayed diagnoses and limited screening in middle-income countries
- **Socioeconomic Changes:** Rising HDI associated with increased CRC mortality due to lifestyle shifts

# CRC in Latin America: The role of Westernization

Estimated Annual Percentage Increase in CRC Incidence Rates (1983–2012)



Sources:

1. Curado MP et al. (2016). Cancer incidence in five continents: Volume X. IARC.
2. Sierra MS et al. (2016). Cancer patterns and trends in Central and South America. *Cancer Epidemiology*, 44(Suppl 1), S23-S42.
3. Muzzi CD et al. (2023). Trends in colorectal cancer mortality in Latin America: A 30-year analysis. *PLOS One*.

# Early-onset CRC in US Latinos

- Early-onset CRC (EO-CRC) is high among U.S. Latinos, accounting for 17% of all CRC cases.
- Puerto Ricans had the highest incidence (12.18 per 100,000) and the highest increase in incidence trend (AAPC = 2.68, 95% CI: 1.83–3.51).
- The study emphasizes the ethnic diversity within Latinos and highlights the importance of disaggregated Latino cancer epidemiology data.

**Disparities in Colorectal Cancer Incidence Trends Among Hispanics Living in Puerto Rico (2000–2021): A Comparison With Surveillance, Epidemiology, and End Results (SEER) Database**

Luis D. Borrero-García<sup>1</sup> | Marilyn Moró-Carrlón<sup>1</sup> | Carlos R. Torres-Ciurrón<sup>2</sup> | Hilmaris Centeno-Girón<sup>1</sup> | Victoria Pizarro<sup>3</sup> | Taymaralí Santos-Collón<sup>4</sup> | María González-Pons<sup>5</sup>

# Machismo-related barriers for screening

- Stigma and fear around procedures like colonoscopy
- Perceived threat to masculinity (e.g., vulnerability, invasiveness)
- Health minimization (the belief that men should not seek help)
- Concerns about sexual identity in relation to invasive procedures
- Lack of culturally sensitive communication from providers

# Why should we focus on CRC screening?

Table 2. Estimates of Current and Increased Use of US Preventive Services Task Force-Recommended Cancer Screenings Over the Lifetime of Study Cohort, United States, 2018

Preventive Service	Current Use, % <sup>a</sup>	Current Impact (Deaths Prevented) <sup>a</sup>	Incremental Impact (Deaths Prevented) With Increased Screening	
			Increase Screening by 10 Percentage Points <sup>b</sup>	Increase Screening to 90% <sup>b</sup>
Breast cancer screening of 50-year-old women until the age of 74	78.3	10,179	1,300	1,521
Cervical cancer screening of 21-year-old women until the age of 65	79.9	27,166	3,400	3,434
Colorectal cancer screening of 50-year-old adults until the age of 75	67.7	74,470	11,000	24,530

<sup>a</sup> Source: Behavioral Risk Factor Surveillance System Prevalence and Trends Data (7).


<sup>b</sup> Model-based estimates by authors.

Source: Krishna et al, Prev Chronic Dis, 2020


# CRC screening in California Latinos

## A Cancer Health Needs Assessment Reveals Important Differences Between US-Born and Foreign-Born Latinos in California

Juanita Elizabeth Guino<sup>1,2</sup>, Fabian Pérez<sup>1,2,3</sup>, Angelica Pérez<sup>1</sup>, April Fongia Yang<sup>1,2</sup>,  
 Leonie Avendano<sup>1</sup>, Julie Dang<sup>1</sup>, Moon S. Chen Jr.<sup>1</sup>, Alexa Morales Arana<sup>1,2</sup>,  
 Sienna Rocha<sup>1,2</sup>, William Kuno<sup>1,2</sup>, Primo N. Lara Jr.<sup>1</sup>, Laura Fejerman<sup>1,2</sup> and  
 Luis G. Carrasjal-Carrona<sup>1,2,3</sup>



# We implemented a culturally- and linguistically-appropriate model for CRC education in farmworker communities.



The figure above describes the top 3 questions observed with highest pre to post difference in knowledge gained from participants who took part in the survey after receiving colorectal cancer education through the inflatable colon.

**900**

Community members reached

**173**

CRC knowledge Surveys collected

**>40**

Community organizations participated

# Poverty increases CRC mortality

**Table 2.** Comparisons of 2007–2011 cancer mortality rates for the entire United States versus counties defined by persistent poverty.

	Nonpersistent poverty (ref)		Persistent poverty		% Diff	Unadjusted difference		Adjusted difference	
	Mean	SE	Mean	SE		Est.	<i>P</i>	Est.	<i>P</i>
All cancer types	179.3	0.6	201.3	1.8	12.3	22.0	<0.0001	8.3	<0.0001
Lung and bronchus	52.3	0.3	60.9	1.0	16.5	8.6	<0.0001	2.9	<0.001
Colorectal	17.1	0.1	20.1	0.3	17.7	3.0	<0.0001	1.7	<0.0001
Breast	21.6	0.2	24.1	0.5	11.9	2.6	<0.0001	0.9	0.10
Prostate	22.8	0.2	28.2	0.7	24.0	5.5	<0.0001	1.1	0.08
Cervical	2.5	0.1	3.7	0.2	50.1	1.2	<0.0001	0.4	0.07
Oropharyngeal	2.5	0.0	3.2	0.1	29.6	0.7	<0.0001	0.1	0.38
Stomach	2.9	0.0	4.1	0.2	43.2	1.3	<0.0001	0.4	0.01
Liver and intrahepatic bile duct	5.0	0.1	6.3	0.2	27.6	1.4	<0.0001	0.5	<0.01

Note: Cancer mortality rates are expressed as deaths per 100,000 people per year except breast and cervical cancers (deaths per 100,000 females per year) and prostate cancer (deaths per 100,000 males per year). Two-sample *t* tests were used to estimate unadjusted differences in cancer mortality rates for counties not in persistent poverty (reference category) versus counties in persistent poverty, and multivariate linear regressions were used to estimate adjusted differences in cancer mortality rates. Adjusted models controlled for county-level metropolitan status; Census region; percentage of residents who are female, non-Hispanic black, Hispanic, with a bachelor's degree or higher, and unemployed; and median household income.

Abbreviations: Diff, difference; Est., estimate; ref, reference; SE, standard error.

# We are studying the impact of income support programs on CRC patterns

The screenshot shows the website for the Upstream Research Center, specifically for Research Project 2: CalEITC and Colorectal Cancer. The header includes the logo and navigation links: ABOUT, OUR WORK, MEET THE TEAM, PILOT GRANTS, and FELLOWSHIP. The main content area features a description of the project, an 'Investigators' section with eight team members, and a footer with contact information.








**UPSTREAM** Upstream Research Center  
Co-led by Stanford, UC Davis and UC San Francisco

ABOUT OUR WORK MEET THE TEAM PILOT GRANTS FELLOWSHIP

## Research Project 2: CalEITC and Colorectal Cancer

The Center is also evaluating the impact of increased income support through the Earned Income Tax Credit (EITC). The project will estimate the effect of the 2015 CalEITC expansion policy on colorectal risk factors. The examination of these effects in California is notable because the state has one of the most generous EITC policies for lower-income individuals and having a social security number is no longer required to receive benefits, opening eligibility up to non-US citizens with an individual Taxpayer Identification Number (ITIN).

### Investigators


 <p><b>Luis E. Castañeda-Camino, PhD</b> Associate Vice Chancellor, Office of Academic Services, UC Davis; Funding Director, Latinos United for Cancer Health Advancement and Center for Advancing Cancer Health Equity, UC Davis Comprehensive Cancer Center; Co-director, Community Engagement Program, UC Davis Clinical and Translational Science Center Project Lead</p>	 <p><b>David Rakkyol, Sc.D., MPH</b> Director, Stanford Center for Population Health Sciences Project Lead</p>
 <p><b>Scarlett Lin Gomez, PhD</b> Co-Leader, Cancer Control Program, UCSF Helen Diller Family Comprehensive Cancer Center</p>	 <p><b>Patricia Rodrigues Espinosa, PhD</b> Care Associate Leader, Stanford Alzheimer's Disease Research Center; Associate Director of Research, Stanford School of Medicine Office of Community Engagement</p>
 <p><b>Lisa Solomon Weiss, PhD</b> Associate Director, Community Engagement, Stanford Center for Population Health; Co- Director of Community- Engaged Research, Office of Cancer Health Equity, Stanford Cancer Institute; Faculty Director, Office of Community Engagement, Stanford School of Medicine</p>	 <p><b>Michael Potter, MD</b> Director, San Francisco Bay Collaborative Research Network; Director, CTSI Research Infrastructure Network and Translational Programs; Family physician and researcher, UCSF</p>
	 <p><b>Maxwell Rang, PhD</b> PhD student scholar, Stanford Department of Sociology</p>

CONTACT: 650.725.7000 | [www.upstreamcenter.org](http://www.upstreamcenter.org)

# Persistent Poverty Map

- The risk of dying from cancer is greatly influenced by your zip code.
- If you live in a poor neighborhood, you face cancer death rates that are 12% higher than if you live in a wealthy neighborhood.

Thanks to Scarlet Gomez for providing the figure



# Concluding Remarks

- CRC is major driver of cancer incidence, mortality and disparities in Latinos
- CRC is highly preventable, but screening rates remain stubbornly low
- Effective interventions to increase screening require holistic approaches
- Men have low screening rates, interventions addressing sex-specific barriers need to be implemented

## Acknowledgements

# The Health Equity Leadership, Science and Community Laboratory (The LCC Lab)



### Funding:

- NIH/NCI:
  - R01CA223978 (DCCPS)
  - R21CA199631 (CRCHD)
  - U54CA233306 (CRCHD)
  - U54CA283766 (CRCHD)
  - U54CA280911 (DCCPS)
  - D43CA260869 (Global Health)
  - Diversity (Cuellar-Vitte, Diaz, Halmaj, Morales, Quino, Vang) and Administrative (Global health, CRCHD) Supplements
- Gilead, Genentech
- Our collaborators and trainees

# Health is Wealth - Cancer's Economic Toll

- 46% skip recommended treatments due to cost concerns
- Latino cancer survivors face 2 to 3x higher healthcare costs
- 71% of survivors carry medical debt
- Financial impact reverberates through families and communities
- \$8.8 billion lost annually in productivity due to Latino cancer deaths



# Costs of Early vs Late Diagnosis of Prostate Cancer

A Latino man's lifetime economic contribution is ~\$2.17 million  
 Based on a \$48,000 annual wage (average annual salary for a Latino male) over a 45-year career

Scenario	Treatment & Estimated Work Absence	Healthcare Cost	Lost Wages Calculation (Absence x Annual Income)	Total Loss on U.S. Economy (Lost Wages x New Prostate Cancer Cases Annually)
Early Detection and Care	3-month absence, then full return to work until retirement	\$27,500	0.25 x \$48,240 = \$12,060	\$12,060 x 12615 patients = \$152.1 million
Late Detection and Care	6-month absence, then forced to retire 10 years early	\$77,000	(0.5 + 10) x \$48,240 = \$506,520	\$506,520 x 7699 patients = \$3.9 billion
No Intervention / Early Death	Death occurs with 20 years of potential work life remaining	\$0	20 x \$48,240 = \$964,800	\$964,800 x 2586 patients = \$2.5 billion

Presentation by Matthew "Mateo" Banegas, PhD, UCSD  
 Sept 12th, Forum 1



# The Enigmatic Male Predominance of Gastric Cancer

**María Constanza Camargo, PhD, MS, MHA**

DCEG Women Scientist Advisor's Mentoring and Leadership Award (2022), Senior Investigator, Metabolic Epidemiology Branch, National Cancer Institute (NIH/NCI), MD



# The enigmatic male predominance of gastric cancer


**Maria Constanza Camargo**

Senior Investigator

Division of Cancer Epidemiology and Genetics

# Key Messages

- Gastric cancer shows a clear male predominance.




Data source: GLOBOCAN 2022  
 Graph production: IARC  
<http://gco.iarc.fr/today>  
 World Health Organization

# Key Messages

- Gastric cancer shows a clear male predominance.
- There are persistent racial and ethnic disparities in gastric cancer incidence, mortality and survival in the United States.

**Stomach**  
**SEER 5-Year Age-Adjusted Incidence Rates, 2017-2021**  
**By Race/Ethnicity and Sex, All Ages, All Stages**

**Estimated cases in 2025: 30,300**



**Data Source:**  
 • SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries [<https://seer.cancer.gov/registries/terms.html>].


**Methodology:**  
 • Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

**Race/Ethnicity Coding:**  
 • For more details on SEER race/ethnicity groupings, please see Race and Hispanic Ethnicity Changes [[https://seer.cancer.gov/seerstat/variables/seer/race\\_ethnicity/](https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/)].  
 • Rates for American Indians/Alaska Natives only include cases that are in a Purchased/Referred Care Delivery Area (PRCDA).  
 • Incidence data for Hispanics and Non-Hispanics are based on the NAACCR Hispanic Latino Identification Algorithm (NHIA).

**Cancer Site Coding:**  
 • See SEER\*Explorer Cancer Site Definitions [<https://seer.cancer.gov/statistics-network/explorer/cancer-sites.html>] for details about the cancer site coding used for SEER Incidence data.

Created by <https://seer.cancer.gov/statistics-network/explorer> on Sat May 11 2024.

# National age-standardized gastric cancer mortality rates, 2000-2019, by year and racial and ethnic group



**Estimated deaths  
in 2025: 10,870**


- Black
- Latino
- AIAN
- Asian
- White
- Total

**Stomach**  
**SEER 5-Year Relative Survival Rates, 2014-2020**  
**By Race/Ethnicity, Both Sexes, All Ages, All Stages**

5-Year  
Relative Survival

**37.9%**

2014-2021



**Data Source:**

- SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries (<https://seer.cancer.gov/registries/terms.html>) (excluding Illinois and Massachusetts)
- Expected Survival Life Tables (<https://seer.cancer.gov/exp/survival/>) by Socio-Economic Standards

**Methodology:**

- The five-year survival rates are calculated using monthly intervals.

**Race/Ethnicity Coding:**

- For more details on SEER race/ethnicity groupings, please see Race and Hispanic Ethnicity Changes ([https://seer.cancer.gov/seerstat/variables/seer/race\\_ethnicity/](https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/))
- Incidence data for Hispanics and Non-Hispanics are based on the NAACCR Hispanic Latino Identification Algorithm (NHIA).
- Rates for American Indians/Alaska Natives only include cases that are in a Purchased/Referred Care Delivery Area (PRCDA)

**Cancer Site Coding:**

- See SEER\*Explorer Cancer Site Definitions (<https://seer.cancer.gov/statistics-network/explorer/cancer-sites.html>) for details about the cancer site coding used for SEER incidence (IIR)

Created by <https://seer.cancer.gov/statistics-network/wkipower> on Fri May 11 2024

# Age-Standardized Rate (World) per 100 000, Incidence, Both sexes, in 2022

## Stomach




All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

**Cancer TODAY | IARC**  
<https://gco.iarc.who.int/today>  
 Data version: Globocan 2022 (version 1.1) - 08.02.2024  
 © All Rights Reserved 2024

## Observed survival, 5-year, both sexes, cases diagnosed 2008-2012

Stomach, Latin America, Observed survival

\* Median survival estimate for the country



# Key Messages

- Gastric cancer shows a clear male predominance.
- There are persistent racial and ethnic disparities in gastric cancer incidence, mortality and survival in the United States.
- Chronic *Helicobacter pylori* infection is the primary cause of gastric cancer, and there is a persistently high prevalence in some populations.

# *H. pylori* was responsible for ~80% of new gastric cancer cases





	Total		
	New cases	New cases attributable to infectious pathogens	
<i>Helicobacter pylori</i>			
Non-cardia gastric cancer	850 000	760 000	<b>90%</b>
Cardia gastric cancer	180 000	36 000	<b>20%</b>
Non-Hodgkin lymphoma of gastric location	22 000	16 000	<b>72%</b>



**61%** of **cardia** cancer cases in East Asia could be attributable to *H. pylori* infection.


Han *et al.*, *Helicobacter* 2023

# *H. pylori* seropositivity by age in the US population, NHANES




# Seroprevalence and Determinants of *Helicobacter pylori* Infection in the Hispanic Community Health Study/Study of Latinos

Sabrina H. Tsang,<sup>\*</sup> M. Larissa Avilés-Santa,<sup>‡</sup> Christian C. Abnet,<sup>\*</sup> Maximo O. Brito,<sup>§</sup> Martha L. Daviglius,<sup>||</sup> Sylvia Wassertheil-Smoller,<sup>¶</sup> Sheila F. Castañeda,<sup>#</sup> Sharon Minnerath,<sup>\*\*</sup> Gregory A. Talavera,<sup>#</sup> Barry I. Graubard,<sup>\*</sup> Bharat Thyagarajan,<sup>\*\*</sup> and M. Constanza Camargo<sup>\*</sup>




# Seroprevalence and determinants of *H. pylori* infection in the Hispanic Community Health Study/Study of Latinos (n=16,144)

A U.S. Born participants



Overall weighted seroprevalence: 38%

B Born outside of the U.S.



Overall weighted seroprevalence: 62%

# Key Messages

- Gastric cancer shows a clear male predominance.
- There are persistent racial and ethnic disparities in gastric cancer incidence, mortality and survival in the United States.
- Chronic *Helicobacter pylori* infection is the primary cause of gastric cancer, and there is a persistently high prevalence in some populations.
- While lifestyle factors contribute, a significant portion of the male excess in risk is unexplained and likely due to biological factors.



# Risk Factors More Common in Men

- *H. pylori* infection: Men, both adults and children, have a slightly higher prevalence.
- Smoking and alcohol: Men exhibit greater intensity of smoking and alcohol consumption.
- Dietary factors: Men tend to have diets higher in salt, smoked foods, and processed meats.

# Key Messages

- Gastric cancer shows a clear male predominance.
- There are persistent racial and ethnic disparities in gastric cancer incidence, mortality and survival in the United States.
- Chronic *Helicobacter pylori* infection is the primary cause of gastric cancer, and there is a persistently high prevalence in some populations.
- While lifestyle factors contribute, a significant portion of the male excess in risk is unexplained and likely due to biological factors.
- **Gastric cancer is largely preventable.**

# Eradication Therapy to Prevent Gastric Cancer in *Helicobacter pylori*-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies



# Latin America and the Caribbean Code against Cancer

*Learn how to help prevent cancer  
in yourself and your family*



**12.** Infection from *Helicobacter pylori* bacteria can cause stomach cancer. Check with health professionals to find out if you might benefit from screening and treatment for this bacterial infection.

Herrero *et al.*, Cancer Epidemiol 2023; Camargo *et al.*, Lancet Reg Health Am 2023





# Population-Based *Helicobacter pylori* Screen-and-Treat Strategies for Gastric Cancer Prevention: Guidance on Implementation

IARC Working Group Reports, Volume 12

Edited by Jin Young Park

2025












ISBN-13

978-92-832-4528-5





# A summary of the National Cancer Institute Think Tank on Advancing Gastric Cancer Prevention

M. Constanza Camargo , PhD, MS, MHA<sup>\*1</sup>, Christian C. Abnet , PhD, MPH<sup>1</sup>, Jeremy L. Davis , MD<sup>2</sup>, Cecilia Monge , MD, MPH<sup>2</sup>, Tram Kim Lam , PhD, MPH<sup>3</sup>, Satish Gopal, MD, MPH<sup>4</sup>, Matthew Young , PhD<sup>5</sup>, Phil Daschner , MS<sup>6</sup>, Tiffany A. Wallace , PhD<sup>7</sup>, Luz María Rodríguez, MD<sup>5</sup>, Philip E. Castle , PhD, MPH<sup>1,5</sup>, Asad Umar , DVM, PhD<sup>5</sup>, Ellen Richmond , MS<sup>5</sup>

Research opportunities in the US and other low- and moderate-risk countries include testing the usability of early detection and prevention strategies with existing evidence of effectiveness and efficiency in high-risk East Asian countries.



Research

JAMA | **Original Investigation**

# Screening for *Helicobacter pylori* to Prevent Gastric Cancer A Pragmatic Randomized Clinical Trial

Yi-Chia Lee, MD, PhD; Tsung-Hsien Chiang, MD, PhD; Han-Mo Chiu, MD, PhD; Wei-Wen Su, MD; Kun-Ching Chou, MD; Sam Li-Sheng Chen, PhD; Amy Ming-Fang Yen, PhD; Jean Ching-Yuan Fann, PhD; Sherry Yueh-Hsia Chiu, PhD; Shu-Lin Chuang, PhD; Yi-Ru Chen, MSc; Shih-Dian Chen, MD; Tsung-Hui Hu, MD, PhD; Yi-Jen Fang, MD, PhD; Ming-Shiang Wu, MD, PhD; Tony Hsiu-Hsi Chen, PhD; Yen-Po Yeh, MD, PhD; for the Collaborators of Taiwan Community-based Integrated Screening Group



EDITORIAL

## Fecal Immunochemical Test and *Helicobacter pylori* Stool Antigen Co-Testing A Potential Approach for Gastric Cancer Screening

M. Constanza Camargo, PhD, MSc, MHA





Clinical Research in Hepatology and Gastroenterology 43 (2021) 100907



Available online at  
**ScienceDirect**  
www.elsevier.com/locate/jgh

Elsevier Masson France  
**EM|consulte**  
www.em-consulte.com/en



ENDOSCOPY

**Opportunistic upper endoscopy during colonoscopy as a screening strategy for countries with intermediate gastric cancer risk**

Joel Wen Liang Lau,<sup>a,\*</sup> Mark Junn Wei Khoo,<sup>b</sup> Xue Hao Leong,<sup>c</sup> Tian Zhi Lim,<sup>a</sup> Asim Shabbir,<sup>d</sup> Khay Guan Yeoh,<sup>e,f</sup> Calvin Janyal Koh<sup>g</sup> and Jimmy Bok Yan So<sup>h,i</sup>

<sup>a</sup>Department of Surgery, <sup>b</sup>Division of General Surgery (Upper Gastrointestinal Surgery), <sup>c</sup>Department of Surgery, <sup>d</sup>Division of Gastroenterology and Hepatology, <sup>e</sup>Department of Medicine, National University Hospital, and <sup>f</sup>Yang Lee Lin School of Medicine, National University of Singapore, Singapore

ORIGINAL ARTICLE

**Systematic upper endoscopy concomitant with colonoscopy performed within the colorectal cancer screening program: Impact on the patients' management**

Orianne Planade<sup>a</sup>, Brigitte Dessomme<sup>b</sup>, Nicolas Chapelle<sup>a</sup>, Marine Verdier<sup>a</sup>, Emilie Duchalais<sup>a</sup>, Lucille Queneherve<sup>a</sup>, Marc Le Rhun<sup>a</sup>, Emmanuel Coron<sup>a</sup>, Jean-Francois Mosnier<sup>c</sup>, Tamara Matyslak-Budnik<sup>d,e</sup>, Yann Touchefeu<sup>f</sup>

Best Practice & Research Clinical Gastroenterology 35 (2021) 101994



Article


**Prevalence of Abnormalities at Tandem Endoscopy in Patients Referred for Colorectal Cancer Screening/ Surveillance Colonoscopy**

George Triadafilopoulos



Contents lists available at [ScienceDirect](#)  
**Best Practice & Research Clinical Gastroenterology**

journal homepage: [www.elsevier.com/locate/bprc](http://www.elsevier.com/locate/bprc)



**Cost-effectiveness of upper endoscopy for gastric cancer screening and surveillance in Western populations**

N.E.A. Kapteijn<sup>a</sup>, D.T. Mulder<sup>b</sup>, I. Lamidor-Vogelaar<sup>b</sup>

<sup>a</sup>Department of Gastroenterology, Erasmus MC University Medical Center Rotterdam, the Netherlands  
<sup>b</sup>Department of Public Health, Erasmus MC University Medical Center Rotterdam, the Netherlands



# Updated and New Clinical Guidelines in the US

---

## ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection

William D. Chey, MD, FAGG<sup>1</sup>, Colin W. Howden, MD, FAGG<sup>2</sup>, Steven F. Moss, MD, FAGG<sup>3</sup>, Douglas R. Morgan, MD, MPH, FAGG<sup>4</sup>, Katarina B. Greer, MD, MSEd<sup>5</sup>, Shilpa Grover, MD, MPH<sup>6</sup> and Shailja C. Shah, MD, MPH<sup>7</sup>

*Am J Gastroenterol* 2024;119:1730–1753. <https://doi.org/10.14309/ajg.0000000000002968>; published online September 4, 2024

---

CME

## ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions

Douglas R. Morgan, MD, MPH, FAGG<sup>1</sup>, Juan E. Corral, MD, MPH<sup>2</sup>, Dan Li, MD<sup>3\*</sup>, Elizabeth A. Montgomery, MD<sup>4</sup>, Arnaldo Riquelme, MD<sup>5</sup>, John J. Kim, MD, FAGG<sup>6</sup>, Bryan Saub, MD, MSc, FAGG<sup>7</sup> and Shailja C. Shah, MD, MPH<sup>8,9</sup>

*Am J Gastroenterol* 2025;120:709–737. <https://doi.org/10.14309/ajg.0000000000003350>

---

## Quality Indicators for Upper GI Endoscopy

Rena Yadlapati, MD, MSHS, FAGG<sup>1</sup>, Dayna Early, MD, FAGG<sup>2</sup>, Prasad G. Iyer, MD, MSc, FAGG<sup>3</sup>, Douglas R. Morgan, MD, MPH, FAGG<sup>4</sup>, Neil Sengupta, MD, MPH, FAGG<sup>5</sup>, Prateek Sharma, MD, FAGG<sup>6</sup> and Nicholas J. Shaheen, MD, MPH, MACG<sup>7</sup>

*Am J Gastroenterol* 2025;00:1–23. <https://doi.org/10.14309/ajg.0000000000003252>

# Call to action

- To raise gastric cancer awareness.
- To build a far-reaching and well-funded national research agenda addressing prevention and control strategies.

# Division of Cancer Epidemiology and Genetics (DCEG)

## Join our fellowship training program!

Get started at [dceg.cancer.gov](https://dceg.cancer.gov)



**DCEG's mission** is to discover the causes of cancer and inform the means of prevention through epidemiological and genetic research.



NATIONAL  
CANCER  
INSTITUTE

# Using Artificial Intelligence

What do you primarily use AI for? (Select all that apply)

Answer Choice	0%	100%	Number of Responses	Responses Ratio
Research/literature review			7	43%
Writing assistance			9	56%
Data analysis			1	6%
Patient/client communication			0	0%
Grant applications			0	0%
Translation services			3	18%
Health information searches			4	25%
Educational content creation			6	37%
Not applicable			5	31%
Other			0	0%
<b>Total Responses</b>			<b>16</b>	<b>100%</b>

61% - Using AI a year or less

53% - Very or somewhat comfortable using AI

92% - **Algorithmic bias,** equal access, few Latinos in AI development, data privacy

\* Small sample size – 16 respondents



# Making AI Work for You: The Benefits and Risks of Using Artificial Intelligence for Health Questions

**Enrique Velazquez-Villarreal, MD, PhD, MPH, MS**

Physician-Scientist and Computational Geneticist, Expertise in Multi-Omics Research, Assistant Professor, Department of Integrative Translational Sciences, City of Hope, Duarte Cancer Center, CA

## Making AI Work for You: The Benefits and Risks of Using Artificial Intelligence for Health Questions

**Enrique Velazquez-Villarreal,  
MD, PhD, MPH, MS**


Assistant Professor  
Department of Integrative Translational Sciences  
City of Hope, Comprehensive Cancer Center





**AI-HOPE-TGFbeta: A Conversational AI Agent for Integrative Clinical and Genomic Analysis of TGF- $\beta$  Pathway Alterations in Colorectal Cancer to Advance Precision Medicine**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde  
 doi: <https://doi.org/10.1093/bioinformatics/btad001>



About us

Frontiers in Artificial Intelligence

Follow this preprint

**Conversational AI Agent for Precision Oncology: AI-HOPE-WNT Integrates Clinical and Genomic Data to Investigate WNT Pathway Dysregulation in Colorectal Cancer**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde  
 doi: <https://doi.org/10.1101/2023.05.08.5327180>



THE PREPRINT SERVER FOR HEALTH SCIENCES

Follow this preprint

**Conversational Artificial Intelligence for Translational Precision Medicine: Integrating Social Determinants of Health, Genomics, and Clinical Data with AI-HOPE-PM**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde  
 doi: <https://doi.org/10.1101/2023.01.28.23121844>



THE PREPRINT SERVER FOR HEALTH SCIENCES

Follow this preprint


**Precision Oncology Through Dialogue: AI-HOPE-RTK-RAS Integrates Clinical and Genomic Insights into RTK-RAS Alterations in Colorectal Cancer**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde  
 doi: <https://doi.org/10.1101/2023.04.25.23121154>



**From Mutation to Prognosis: AI-HOPE-PI3K Enables Artificial Intelligence Agent-Driven Integration of PI3K Pathway Data in Colorectal Cancer Precision Medicine**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde



*cancers*

**Decoding the JAK-STAT Axis in Colorectal Cancer with AI-HOPE-JAK-STAT: A Conversational Artificial Intelligence Approach to Clinical-Genomic Integration**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde



THE PREPRINT SERVER FOR HEALTH SCIENCES

Follow this preprint

**Artificial intelligence for precision oncology: AI-HOPE-MAPK uncovers clinically actionable MAPK alterations in colorectal cancer**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde  
 doi: <https://doi.org/10.1101/2023.06.11.23127444>



THE PREPRINT SERVER FOR HEALTH SCIENCES

Follow this preprint

**Artificial Intelligence Agent: AI-HOPE-TP53 Enables Pathway-Centric Analysis of TP53-Driven Molecular Alterations in Colorectal Cancer Precision Oncology**

by E-Wen Yang, Enrique Velasco-Villaverde, and Enrique Velasco-Villaverde  
 doi: <https://doi.org/10.1101/2023.05.23.23121813>


## Outline

- AI revolution
- Conversational AI-Agent
- Build Latino-Focused CRC AI
- Benefits & Risks of Using AI for Health Questions
- “SAFE STEPS”



- Molecular Characterization of Colorectal Cancer
- AI-Agents Development
- Precision Oncology for CRC







• Multi-Omics



• Big Data



• Artificial Intelligence



# AI Revolution



2017

2020

2022

2023

2024

2025

Google paper  
“Attention  
is all you  
Need”

GPT 3 –  
Open AI


GPT 3.5 –  
ChatGPT

LLaMA  
ChatGPT-4  
Reasoning  
Thinking

Vibe coding Era  
LlamaCon



## AI AGENT ARCHITECTURE



AI-HOPE  
AI-PM

Table 1. Levels of autonomous AI agents	Autonomous agents	Supervised generation	Experimental design	Reasoning	Human-AI collaboration
Level 0: no AI agents	ML models perform predefined tasks, with no adaptive changes to the prompts.			None	scientist defines the hypothesis and sometimes sets the output of ML. Assists to help with prompt-based generation; scientist defines the task to feed hypothesis; scientist completes tasks.
Level 1: AI agents as assistants	AI agent formulates simple and narrow hypothesis that are a direct composition of existing knowledge; generating data, in observance.		simple design of experimental protocols and utilization of in silico and experimental tools.	simple reasoning in a selected task; rudimentary summary of findings; use of experimental data and existing knowledge.	scientist defines the hypothesis; scientist defines the series of tasks to test hypothesis; AI agent formulates tasks.
Level 2: AI agents as collaborators	AI agent generates hypothesis that are an explicit continuation of data trends in a domain; iterative.		design of rigorous experimental protocols and adapt utilization of a broad-range of in silico tools; some data are collected; employ statistical and computational methods to analyze the results and account the data to determine whether it supports or refutes the hypothesis.	iterative reasoning with existing knowledge; considering alternative explanations; and assessing the reliability and validity of the biological synthesis of evidence for sound inferences; collaborating with other researchers and undergoing peer review to validate findings; and ensure that publications are useful and credible.	scientist proposes initial hypothesis and refines hypothesis together with AI agent; AI agent defines the series of tasks to test hypothesis; AI agent completes tasks.
Level 3: AI agents as executors	AI agent generates precise, in-depth hypothesis that are beyond extrapolations from existing knowledge.		development of experimental methods; actively gathering data through experiments in synchrotron or genomics; using various techniques and tools to measure and record biological phenomena.	based on the results and interpretations, refine experimental approaches; for continuous learning and adaptation to improve the accuracy and depth of understanding; find creative, innovative and clear conceptual links between findings.	scientist and AI agent together form hypothesis; AI agent defines the series of tasks to test hypothesis; AI agent completes tasks.

AI agents are distinguished by the extent of autonomy in biological systems, which are defined based on the capabilities of AI agents to complete different tasks in the discovery process. At level 0, there is no AI agent, and the scientist uses LLM as a tool. Level 1 consists of AI agents as assistant executors, where agents complete a set of narrow and specific tasks defined by scientists. At level 2, AI agents act as collaborators and can use a broad set of tools to identify scientific discoveries. Next, they can only generate hypotheses that are a direct continuation of observations. Finally, at level 3, AI agents act similarly to human scientists, across several areas of human expertise, capable of identifying and understanding promising discoveries and creating novel hypotheses that cannot be derived from existing knowledge.

---

## Conversational Artificial Intelligence

---

# WHAT IS AN AI AGENT ?

A SIMPLE GUIDE TO AI AGENTS AND THEIR FUNCTIONS



AI-HOPE: An AI-Driven conversational agent for enhanced clinical and genomic data integration in precision medicine research  
Wen Yang, Enrique Velazquez Villarreal

# AI AGENT



CANCER DISCOVERY News

SHARE



## Autonomous AI System Takes On Cancer Treatment Planning



July 2, 2025

A new AI platform turns a general-purpose language model into an autonomous clinical agent that can analyze diagnostic tests, interpret imaging and pathology, and generate treatment plans for patients with cancer—entirely without human input. Although still a proof-of-concept, the system marks a key step toward AI-guided oncology, with tools that could soon augment or streamline decisions from tumor boards.

Eric Dodge

DOI: <https://doi.org/10.1158/2158-4090.CCR25-0557>

Publisher: American Association for Cancer Research

AI-HOPE

First ARTIFICIAL INTELLIGENCE AGENT combining Clinical and Genomic data for Precision Oncology Research

Velazquez-Villarreal Lab



## Why This Matters

---

AI is a helper, not a doctor

- A family story: using questions + doctor visits to solve a health issue
- AI helped us organize symptoms and questions
- The doctor did the testing and treatment
- Lesson: Use AI to prepare; decisions happen with your clinician



## AI for Health in 60 Seconds

### What AI can do

- Explain health words in simple terms
- Help make a list of questions for your visit
- Point to trusted sources (CDC, NIH, ACS)



## AI for Health in 60 Seconds

### What AI cannot do

- Diagnose you or replace screening/tests
- Know your full medical history
- Be right 100% of the time



## Why Build AI for Latino Men & CRC?

---

### The need

- Latino men face later diagnoses and barriers to care
- Many studies don't include enough Latino data
- Language and access matter



## Why Build AI for Latino Men & CRC?

### The goal

- Make information relevant and bilingual
- Help men prepare for better clinic visits
- Close gaps in screening and follow-up




## How Our CRC AI Helps

- Plain language approach
- Uses published research and guidelines to teach & guide
- Focuses on questions Latino men actually ask
- Offers Spanish/English explanations
- Flags limits and says when to see a clinician

## How Our CRC AI Helps

### Limits

- Data can be incomplete or biased
- Always verify with a trusted source or your doctor



## What We're Learning About Latino Men & CRC

---

### High-level takeaways

- Screening gaps: many men start too late or skip follow-up
- Symptoms often go unreported (stigma, work, access)
- Diversity within “Latino”: Mexican, Puerto Rican, Central/South American, etc.

## What We're Learning About Latino Men & CRC

### Biology we monitor

- Tumor signals tied to inflammation/immune response
- Genetic tests/biomarkers can guide treatment—ask your doctor

CAN AI HELP  
US MAKE  
BETTER  
DECISIONS?



## What This Means for Your Care

---

### Screening basics

- Most adults: start talking about screening at 45 (earlier with family history or symptoms)
- Tests: FIT stool test or colonoscopy—ask which is right for you

## What This Means for Your Care

---

### If diagnosed

- Ask about biomarker testing and clinical trials
- Bring a family member or friend to appointments

# Benefits & Risks of Using AI

---

## Benefits

- Simple explanations, anytime
- Bilingual support
- Better prep for doctor visits

## Benefits & Risks of Using AI

### Risks

- Wrong/outdated answers
- Bias in data
- Privacy concerns

AI  
AGENT



## Benefits & Risks of Using AI

### Stay safe

- Check the source
- Don't share sensitive IDs
- Confirm with your clinician



## SAFE STEPS

### S — State your goal

- “I’m 47. Should I get screened for colon cancer?”

### A — Add basics (no IDs)


- Age, family history, symptoms in simple words

### F — Find sources

- “List the sources you used.” Look for CDC/NIH/ACS/hospital sites

### E — Explain back

- “Explain like (Personalize...) (in Spanish, please).”



## SAFE STEPS

### S — Show next steps

- “Give me 3 questions to ask my doctor.”

### T — Time check

- “Is this info updated this year?”

### E — Example prompts

- “¿Cuáles son las señales de alerta del cáncer de colon en hombres?”

- “What screening should I ask for at my clinic?”

### P — Protect privacy

- No full name, SSN, exact address, MRN

### S — See a clinician

- Use AI to plan; your doctor makes the medical call

## Providing Instructions Through Conversation

Describe clinical research questions

“Does the frequency of TP53 mutations differ between early- and late-stage CRC?”

Figure suggested research plans

“Yes, this is a case-control study.”

Criteria to select the case samples

“The disease progression is in the late stages (III/IV)”

Criteria to select the control samples

Disease progression is in

B

## Extracting Logic from Human Language



Graphical User Interface



- Reasoning
- Planning



LLMs generate <sup>116</sup>

## Mini-Demo

---

Try this at home

- “I’m a 48-year-old Latino man with no family history. Should I be screened for colon cancer? Explain in simple words and list your sources.”



## Mini-Demo

What to look for


- Clear answer, simple language
- Sources from CDC/NIH/ACS or major hospitals
- Reminder to see a clinician

CAN AI HELP  
US MAKE  
BETTER  
DECISIONS?



## Three Calls to Action

- **Get screened / bring a buddy**
  - If you're 45+ (or have symptoms/family history), talk to your doctor this month
- **2. Use AI wisely**
  - Follow SAFE STEPS; verify sources; take your questions to the clinic
- **3. Build equity together**
  - Ask for Spanish materials, join research, and support Latino scientists/entrepreneurs



## Q&A / Resources

---

### Ask me anything

- CRC screening, symptoms, how to ask AI safely

### Trusted resources

- CDC • NIH/NCI • American Cancer Society • Major academic centers • **Velazquez-Villarreal Lab – City of Hope**

### Remember

- AI helps you prepare; your clinician guides your care



—

Thank you!

---



# AI AGENTS

# The Latino Cancer Institute is Published in Cancer Causes and Control, June 6th 2025



Home > [Cancer Causes & Control](#) > Article

## Climate change, cancer, and the critical importance of Latino community engagement

Comment | [Open access](#) | Published: 06 June 2025 (2025) [Cite this article](#)

[Download PDF](#)  You have full access to this [open access](#) article

[Y. Duron](#) , [A. J. Garcia](#) & [M. Juarez-Vargas](#)

 1398 Accesses [Explore all metrics](#) → <https://link.springer.com/article/10.1007/s10552-025-02019-x>

“It’s time for institutional systems—academic, public health, and government entities—to put aside biased views of community helplessness, and instead embrace them as equal partners, budgets and all.”

1398 accesses as of Sept 30



# Toxic Work, Warming World: Why Latino Men Face Higher Cancer Risks

**Leticia Nogueira, PhD, MPH**

Scientific Director, Surveillance Prevention  
& Health Services Research (SPHeRe)  
American Cancer Society, FL

# Toxic Work, Warming World: Why Latino Men Face Higher Cancer Risks


Leticia M. Nogueira, PhD MPH

# Toxic Work

Latino men are overrepresented in occupations with high exposure to carcinogens

## Latino men are overrepresented in construction and maintenance occupations, but underrepresented in managerial and professional roles

Percent distribution of Latino men workers and all U.S. men workers, by major U.S. occupational group, 2021



Source: U.S. Bureau of Labor Statistics, "Current Population Survey - Employed persons by occupation, race, Hispanic or Latino ethnicity, and sex" [2022].

# Occupational Exposure to Environmental Hazards

Latino men are overrepresented in occupations with high exposure



Agriculture

<https://grist.org/labor/farmworkers-face-harsh-conditions-now-theyre-eyeing-a-pay-cut/>

- Pesticides
- Extreme heat



Construction

<https://www.cpwr.com/wp-content/uploads/DataBulletin-December2024.pdf>

- Asbestos
- Lead
- Silica
- Fumes
- Extreme heat



Service

<https://grist.org/labor/fast-food-workers-dangerous-heat-inside-restaurants/>

- Fumes
- Extreme heat

# Discriminatory Policies and Practices

Perpetuate disproportionate exposure to environmental hazards

## New Deal Labor Laws

- Excluded farmworkers and domestic workers from basic labor protections

## Immigration Status

- H-2A visas tie legal status to employer sponsorship

## Worker Protection Standard

- Allows agricultural practices that would not be tolerated on other industries

# Residential Exposure

Discriminatory policies and practices allow siting of polluting infrastructure near Latinx communities

Toxic Wastes and Race at Twenty:  
1987-2007

*Grassroots Struggles to Dismantle  
Environmental Racism in the United States*




Disproportionate exposure to pollution has been extensively documented

Foundational for the Environmental Justice movement

Bullard, Robert D., Mohai, Paul, Saha, Robin, Wright, Beverly. 2007.  
Toxic Wastes and Race at Twenty: 1987-2007


# Spillover Effect

Discriminatory policies and practices that put Latinx communities at higher risk drive exposure to environmental hazards in the entire population



# Pesticide Exposure

Discriminatory policies and practices that put Latinx communities at higher risk drive exposure to environmental hazards in the entire population



# Exposure to Carcinogens

Cancer clusters along the Houston Ship Channel

Houston Ship Channel





Waterway surrounded by ~600 oil and natural gas processing plants

# Exposure to Carcinogens

Cancer clusters along the Houston Ship Channel

Houston Ship Channel

Impaired



Dioxins




PCBs

TCEQ map showing areas where the water has been deemed "impaired" due to high levels of pollutants

# Exposure to Carcinogens

Cancer clusters along the Houston Ship Channel

Houston Ship Channel



Impaired




<https://www.amnestyusa.org/wp-content/uploads/2024/01/WEB-Petrochemical-The-cost-of-doing-business-v3.pdf>

## SACRIFICE ZONE

According to the United Nations Special Rapporteur on human rights and the environment: "A sacrifice zone can be understood to be a place where residents suffer devastating physical and mental health consequences and human rights violations as a result of living in pollution hotspots and heavily contaminated areas."<sup>9</sup>

# Spillover Effect

Dissipation of air pollution from petrochemical facilities along the Houston Ship Channel



While communities in “Sacrifice Zones” are disproportionately exposed to pollution

As long as these injustices are allowed

People of all backgrounds will continue to be exposed to hazardous pollutants

# Spillover Effect

Water and soil pollution from petrochemical facilities along the Houston Ship Channel



Flooding along the Houston Ship Channel in the aftermath of Hurricane Harvey

Petrochemical plants along the Houston Ship Channel are shown in the aftermath of Tropical Storm Harvey on 29 August 2017.  
© Houston Chronicle via Getty Images (Photographer: Brett Cooper)



# Hurricane Harvey

Flooding hit areas previously assumed to be safe




*Builders Said Their Homes Were Out of a Flood Zone. Then Harvey Came.*



<https://www.nytimes.com/2017/12/02/us/houston-flood-zone-hurricane-harvey.html>

# Warming World

## Climate-driven disasters



Historical Hurricane Paths, Houston TX  
<https://coast.noaa.gov/hurricanes/#map=4/32/-80>

Previous hurricanes paths going through Houston



Extreme Weather Events



Hurricane Harvey


Changing frequency and behavior of extreme weather events makes it harder for communities to prepare and respond to increasingly unpredictable circumstances



Especially concerning for medically vulnerable populations

# Warming World

Climate Change alters the behavior of extreme weather events



Rainfall over Houston during Hurricane Harvey  
National Oceanic and Atmospheric Administration (NOAA)




Warmer air holds more water vapor, which increases the water capacity of hurricanes

# Impact of Hurricanes on Cancer Patients

Disruptions in access to care and worse survival

Figure. Association Between Length of Hurricane Disaster Declaration and Risk of Death in Patients With Lung Cancer Undergoing Radiation



# Disruptions in Access to Care

Climate-driven disasters

Mountainous region, far away from the coast, previously considered a “climate haven”



## IV bags in short supply across US after Hurricane Maria

<https://www.cnn.com/2018/01/16/health/iv-bag-shortage>




## US hospitals strained by IV fluid supply limits after Helene hit production site

<https://www.cnn.com/2024/10/09/health/iv-fluid-shortage-hospitals-hurricane-helene>

JAMA

CLIMATE CHANGE AND HEALTH

## Threats of Weather Disasters for Drug Manufacturing Facilities in the US




Shahzad M, Nogueira LM, Wagner A. *Threats of Weather Disasters for Drug Manufacturing Facilities in the US.* JAMA. Published online August 20, 2025. doi:10.1001/jama.2025.13843

# No Climate Havens

Climate-driven disasters impact people in places previously thought to be safe

“Us versus Them” narrative that is the premise for discriminatory policies and practices falls apart



Hurricane Helene



**3-day estimated rainfall**  
In inches as of Saturday 9 a.m. Eastern



6 12 20 in. or more



Nogueira LM, Salas RN. No climate havens: the expanding threat of climate change to cancer care. Nat Rev Cancer. Published online August 14, 2025. doi:10.1038/s41568-025-00867-y

# Valuable Knowledge and Solutions

Expertise of communities impacted first and worst by environmental hazards



**THE COST OF  
DOING BUSINESS?**

THE PETROCHEMICAL INDUSTRY'S TOXIC  
POLLUTION IN THE USA



Each step in the fossil fuels' lifecycle has detrimental health consequences



According to the United Nations Special Representative on human rights and the environment: "A sacrifice zone can be understood to be a place where human rights violations as a result of living in polluted and contaminated areas."<sup>9</sup>



Climate Change



Fossil Fuels



Exposure to Carcinogens

<https://www.amnestyusa.org/wp-content/uploads/2024/01/WEB-Petrochemical-The-cost-of-doing-business-v3.pdf>

# Valuable Knowledge and Solutions

Expertise of communities impacted first and worst by environmental hazards




Usual data sources won't capture detrimental health outcomes in medically underserved areas

<https://grist.org/project/accountability/wilmington-california-oil-gas-setbacks/>


Communities living in proximity to fossil fuel extraction, processing, and waste management sites have been documenting detrimental health consequences for decades

# Reliance on Fossil Fuels

Shared cause of climate change and rise in exposure to carcinogens



Climate Change



Exposure to Carcinogens

What is one thing I can do?

What is *the next* thing I can do?


# Local Solutions

Find your next action

What brings you joy?

What are you good at?

What work needs doing?



# Local Solutions - Permits

Find your next action



Environmental Impact Statement (EIS) Database

<https://www.epa.gov/eis/eis-database>

AP



ECOMADRES

<https://www.wisconsin.com/article/south-arkansas-dioxide-pipeline-665a20269d43d4aff5944969f869bb03>



Louisiana judge cancels air permits for



[permits for plastics plant | Reuters](#)



<https://earthjustice.org/action/alerts>




Hawaii Advances Pesticide Restrictions for Kauai

<https://www.courthousenews.com/hawaii-advances-pesticide-restrictions-for-kauai/>



# Local Solutions

Cumulative benefits

Number of climate-relevant strategies mentioned in each Comprehensive Cancer Control Plan



Percent of CCCPs with indirect mention of climate change



Number of climate-relevant strategies mentioned



**American Indian  
Cancer  
Foundation**

**District of  
Columbia**

**Federated States  
of Micronesia**

**Northern Mariana  
Island**

**Northwest  
Portland Area  
Indian Health  
Board**

**Puerto Rico**

**Republic of the  
Marshall Islands**

**Alaska Tribal  
Health System**

**South Puget Intertribal  
Planning Agency**

## E. Food System

### Washington

Increase sustainable community gardens in underserved areas.

### Northwest Portland Area Indian Health Board

Traditional and subsistence foods

### Federated States of Micronesia

Let Local Food Be Your Medicine

### California


minimally processed foods

### Alaska Tribal Health System

Inclusion of traditional foods

### South Puget Intertribal Planning Agency

Traditional and tribal gardens



# Local Solutions - Agriculture

Cumulative benefits




## Environmentally Responsible Food = Healthy Food

- Manufacture
- Shipment
- Waste

## Industrialized Food System

High environmental impact

- Land clearing
- Monocultures
- Heavy machinery
- Processing
- Packaging
- Herbicides, pesticides, fertilizers
- Additives



# Identify Potential Partners

Focus on solutions with cumulative benefits



Agriculture



What do we want to accomplish?

Who else would care about this



coming clean




CANCER FREE ECONOMY NETWORK



# Spillover Effect

Consequences of discriminatory policies and practices



Lawn maintenance rules restrict subsistence gardening


Grass is the most commonly irrigated plant, responsible for 1/3 of residential water consumption



Restrictive covenants for ground cover incentivize use of carcinogenic pesticides

# Spillover Effect

Consequences of discriminatory policies and practices



Lawn maintenance rules restrict subsistence gardening



Restrictive covenants for ground cover incentivize use of carcinogenic pesticides




 The Hill

Colorado bans use of gas-powered lawn equipment by state agencies starting 2025

State agencies in Colorado will be banned from using certain gas-powered lawn equipment during the summer, according to a new rule adopted...

# Healthcare and Research Emissions



# Three Choices with Climate Change

We all can contribute to solutions

Environmentally  
responsible  
sustainability  
efforts

**Mitigation**



Emergency  
preparedness and  
response efforts

**Adaptation**



Document ongoing  
suffering and  
increase awareness  
to incentivize  
action

**Solutions**



---

“

Give me a lever long  
enough, and I shall move  
the world.

Archimedes

”

---

# Thank You



# Leukemia in Latino Children

## Catherine Metayer, MD, PhD

Adjunct Professor, Epidemiology and Biostatistics  
Principle Investigator, California Childhood Leukemia  
Study, University of California, Berkeley



# Leukemia in Latino Children

## The Latino Cancer Institute

Webinar | October 3<sup>rd</sup>, 2025


Catherine Metayer, MD, PhD, University of California Berkeley



# Acute Lymphocytic Leukemia (ALL)

## Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2022

### By Race/Ethnicity, Delay-adjusted SEER Incidence Rate, Both Sexes, Ages < 20




Created by <https://seer.cancer.gov/statistics-network/explorer/> on Wed Sep 24 2025




# Clues to Explain Increasing trends of Childhood Leukemia

- Lifestyle--diet
- Environmental exposures
- Immune function /microbiome
- Socioeconomic status
- Gene – Environment interaction

# Hispanic adults



# Non-Hispanic White adults




Prevalence of obesity by US state (2020-2022)  
Highly impacted Latinx communities

Source: <https://www.cdc.gov/obesity/data/prevalence-maps.html>


# Latino communities are burdened with pollution, socioeconomic disadvantages.

CalEnviroScreen 3.0 scores for California census tracts versus the percent of families who identified as being Hispanic.




# Higher Levels of Chemicals in Latino Households in California

Latino homes  
vs.  
non-Latino  
white homes





# Local & Global Research




Childhood Leukemia  
International Consortium



# Risk Factors of Childhood Leukemia


- Immune regulation/infections
- Fetal growth
- Ionizing and non-ionizing radiation
- Environmental exposures
- Diet and supplements
- Genetics
- Epigenetics

**Chemicals are known to cause cancer in adults**




**Genotoxic  
Oxidative stress  
inflammation  
immunotoxic**

# Parental Occupational Exposures to Pesticides



California employs 27% of nation's farmworkers and **the majority are Latinos**

# Occupational Exposures to Pesticides and Childhood Acute Lymphoblastic Leukemia



Adjusted for child's sex, age, ethnicity, mother's race and household income.

Source: Gunier, Env Research (2017)

- Pooled original data for ~8,000 cases and ~14,000 controls
- Maternal exposure – pregnancy **OR=1.01 (0.78-1.30)**
- Paternal exposure – periconception **OR=1.20 (1.06-1.38)**

Source: Bailey, Int J Cancer, 2014

# Dust is an Important Route of Exposure





Fig. 1. Adjusted<sup>a</sup> odds ratios (OR) and 95% confidence intervals for acute lymphocytic leukemia and perinatal paternal occupational pesticide exposure by type of agriculture. <sup>a</sup> Models adjusted for child's sex, age, ethnicity, mother's race and household income.

Source: Gunier, Env Research (2017)



Source: Mother Jones and the Foundation for National Progress Photographer Matt Black



Note: These numbers do not include nonbearing acres with young trees that will start producing when they mature. Source: Annual crop reports from San Joaquin Stanislaus and Merced counties.

Source: California Department of Food and Agriculture (Get the data)

# Paternal Occupational Exposures to Organic Compounds & Childhood ALL

## Positive associations for **Latino Fathers only**

Expert exposure assessment	Cases	Controls	OR*	95% CI
<b>Any organic compounds</b>	<b>107</b>	<b>102</b>	<b>1.72</b>	<b>(1.22-2.44)</b>
-- Benzene	30	20	2.03	(1.11-3.70)
-- Chlorinated hydrocarbons	31	17	2.53	(1.36-4.71)
<b>Combustion exhaust/PAHs</b>	<b>64</b>	<b>56</b>	<b>1.70</b>	<b>(1.16-2.57)</b>


\* OR adjusted for child's age at diagnosis/reference date, sex, maternal race, and household annual income

Source: Metayer, Env Research (2016)


# Maternal Smoking during Pregnancy and Childhood Acute Myeloid Leukemia



Childhood Cancer & Leukemia  
International Consortium



Source: Metayer, AJE, 2016







# Prenatal Vitamin/Folate Supplement and Childhood Acute Lymphoblastic Leukemia

	Latina mothers	Non-Latina whites
Intake	234 cases, 296 controls	265 cases, 374 controls
None	Ref.	Ref.
Moderate intake	1.12 (0.44-2.84)	1.25 (0.75-2.07)
High intake	<b>0.36 (0.17-0.74)</b>	0.76 (0.50-1.16)

Conditional logistic models adjusted for father's education, mother's education, household income, maternal age at child's birth, and nutrient intake from food. N= number of discordant pairs/triplets \*For folic acid, moderate intake is >0 & <600 µg and high intake is ≥600 µg. For vitamins B12, B6, and riboflavin, moderate intake is >0 & <5 µg B12 and <1.5 mg B6 and riboflavin, and high intake is ≥5 µg B12 and ≥1.5 mg B6 and riboflavin.

Source: Singer, Cancer Causes Control, 2016

# Research Translation & Outreach to Families, Community Health Workers & Clinicians





THANK YOU – QUESTIONS?



# Rising Rates of Testicular Cancer in Latino Men

**Katherine A. McGlynn, PhD, MPH**

Senior Investigator, Metabolic Epidemiology Branch,  
National Cancer Institute (NIH/NCI)

# Rising rates of testicular cancer in Latino men

Katherine A. McGlynn, MPH, PhD  
Division of Cancer Epidemiology and Genetics  
National Cancer Institute

# Most commonly occurring cancers in males in the U.S. all ages



- |    |                         |           |                                  |
|----|-------------------------|-----------|----------------------------------|
| 1  | Prostate                | 11        | Liver and Intrahepatic Bile Duct |
| 2  | Lung and Bronchus       | 12        | Stomach                          |
| 3  | Colon and Rectum        | 13        | Myeloma                          |
| 4  | Urinary Bladder         | 14        | Esophagus                        |
| 5  | Melanoma of the Skin    | 15        | Thyroid                          |
| 6  | Kidney and Renal Pelvis | 16        | Brain                            |
| 7  | Non-Hodgkin Lymphoma    | 17        | Tongue                           |
| 8  | Oral Cavity and Pharynx | <b>18</b> | <b>Testis</b>                    |
| 9  | Leukemia                | 19        | Larynx                           |
| 10 | Pancreas                | 20        | Tonsil                           |

# Most commonly occurring cancers in males in the U.S. ages 15-44 years




- 1 Testis**
- 2 Lymphoma
- 3 Colon and Rectum
- 4 Non-Hodgkin Lymphoma
- 5 Melanoma of the Skin
- 6 Thyroid
- 7 Leukemia
- 8 Kidney and Renal Pelvis
- 9 Brain
- 10 Oral Cavity and Pharynx

# Most common cancers in males 15-39 yrs




WORLD	Europe	North America	Latin America	Oceania	Asia	Africa
1 Thyroid	<b>Testis</b>	<b>Testis</b>	<b>Testis</b>	<b>Testis</b>	Thyroid	Kaposi sarcoma
2 <b>Testis</b>	Melanoma	Colorectum	Leukaemia	Melanoma of skin	Leukaemia	Liver
3 Leukaemia	Hodgkin lymphoma	Thyroid	NHL	Colorectum	Oral cavity	NHL
4 NHL	Brain	NHL	Brain	NHL	Colorectum	Colorectum
5 Colorectum	NHL	Leukaemia	Thyroid	Hodgkin lymphoma	Brain	Leukaemia
6 Brain	Thyroid	Hodgkin lymphoma	Colorectum	Leukaemia	Liver	Hodgkin lymphoma
7 Liver	Leukaemia	Brain	Hodgkin lymphoma	Thyroid	NHL	Brain
8 Oral cavity	Colorectum	Melanoma	Prostate	Brain	Lung	Prostate
9 Hodgkin lymphoma	Kidney	Kidney	Stomach	Kidney	<b>Testis</b>	Nasopharynx
10 Lung	Lung	Lung	Lung	Lung	Nasopharynx	Stomach
						Oesophagus
						Lung
						<b>Testis</b>

# Testicular cancer incidence




# Testicular cancer histology




Testicular Germ Cell Tumors

# In utero origin of TGCT




# TGCT incidence rates by age



SEER-12 registries, 1992-2022

# TGCT incidence rates in U.S. males by race and ethnicity



SEER-12 registries, 1992-2022

# TGCT incidence by median age at diagnosis, 2020-2022




## Median age at diagnosis

	TGCT	Seminoma	Nonseminoma
Overall	33	36	29
Non-Hispanic White	35	38	31
Non-Hispanic Black	35.5	37	30
Am Indian/Alaska Native	30	37	24
Asian/Pacific Islander	32	36	29
<b>Hispanic</b>	<b>29</b>	<b>33</b>	<b>26</b>

## Median age of men

Overall	37.7
Non-Hispanic White	44.0
Non-Hispanic Black	34.3
Am Indian/Alaska Nat	27.0
Asian	37.0
Pacific Islander	25.4
<b>Hispanic</b>	<b>30.1</b>

# TGCT incidence by stage at diagnosis, 2022



# TGCT relative 5-year survival for diagnoses in 2016-2017



	Percent five-year survival		
	TGCT	Seminoma	Nonseminoma
Overall	95.6	98.3	92.4
Non-Hispanic White	97.1	98.5	94.8
Non-Hispanic Black	86.2	93.0	80.2
American Indian/Alaska Native	95.6	92.2	100.0
Asian/Pacific Islander	93.8	96.7	90.5
<b>Hispanic/Latino</b>	<b>92.7</b>	<b>97.9</b>	<b>88.8</b>

# Risk associations for TGCT

- Part of the Testicular Dysgenesis Syndrome:
  - Cryptorchidism (undescended testis)
  - Hypospadias (urethra opening on the underside of the penis)
  - Impaired spermatogenesis
  - TGCT
- Personal or family history of TGCT
- Low birthweight
- Shorter gestational age
- Being a twin
- Taller stature
- Cannabis
- Perfluorooctanoic acid (PFOA)
- Organochlorine pesticides



# Calls to action



- Men (15-44 years): practice monthly exams
- Parents: inform sons if they were born with cryptorchism or hypospadias
- Researchers: bank biosamples for future studies

**October 24th, 2025**

# Coming up on the next **Friday Forum Series**

Breast Cancer Awareness Month



Cristhian Gutierrez Huerta,  
6th-year Medical Student,  
National President, LMSA



Elena Rios, MD, MSPH,  
MACP, President, National  
Hispanic Health Foundation



Eric J. Small, MD  
Medical Oncologist, UCSF  
President, ASCO



Javier Rosario, Licensed  
Clinical and Oncology  
Social Worker, Blood  
Cancer United (LLS)



Pat Levitt, PhD  
Chief Scientific Officer and  
Director, Saban Research  
Institute, Children's  
Hospital of LA



Francisco Cartujano-Barrera, MD  
Assistant Professor, Dept Public  
Health Sciences, University of  
Rochester



Ysabel Duron, BA  
TLCI Executive Director

**HR 1. Cristhian Gutierrez Huerta, 6th Year MD/PhD Student, Elena Rios, MD, MSPH, MACP**

**HR 2. Eric Small, MD, Javier Rosario, LCSW, QS, OSW-C, Miriam Juarez-Vargas, BA**

**HR 3. Pat Levitt, PhD , Francisco Cartujano-Barrera, MD, Ysabel Duron, BA**

# SURVEY

Before you leave be sure to take our post-Forum survey.  
We want to know your thoughts.



**ENGLISH**




**SPANISH**

# THANK YOU!

## The Latino Cancer Institute Friday Forum Series Team



Ysabel Duron  
Founder/Executive Director  
The Latino Cancer Institute



Miriam Juarez-Vargas  
Program Manager



Andrea Villafañe  
Graphic Designer



Martin Thiel  
IT/Operations



Viviana Villafañe  
Communication Specialist



Mercy Clark  
Office Administrator



Waleska Santiago  
Video Editor



# THANK YOU

**Ysabel Duron**  
**Founder/Executive Director**  
**The Latino Cancer Institute**  
**[yduro@latinocancerinstitute.org](mailto:yduro@latinocancerinstitute.org)**



THE LATINO CANCER INSTITUTE  
Connect. Convene. Advocate.



Save the Date

The Latino Cancer Institute's

**8th Annual National Forum**

**Fall 2026**



Help Support Our Mission

[www.latinocancerinstitute.org/support-donate](http://www.latinocancerinstitute.org/support-donate)